JP2024513538A5 - - Google Patents

Info

Publication number
JP2024513538A5
JP2024513538A5 JP2024505487A JP2024505487A JP2024513538A5 JP 2024513538 A5 JP2024513538 A5 JP 2024513538A5 JP 2024505487 A JP2024505487 A JP 2024505487A JP 2024505487 A JP2024505487 A JP 2024505487A JP 2024513538 A5 JP2024513538 A5 JP 2024513538A5
Authority
JP
Japan
Prior art keywords
methyl
piperazine
ethyl
dioxo
tetrahydroquinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/086311 external-priority patent/WO2022218296A1/en
Publication of JP2024513538A publication Critical patent/JP2024513538A/ja
Publication of JP2024513538A5 publication Critical patent/JP2024513538A5/ja
Pending legal-status Critical Current

Links

JP2024505487A 2021-04-12 2022-04-12 Parp阻害剤としての置換融合二環式化合物及びその使用 Pending JP2024513538A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110392892.4 2021-04-12
CN202110392892 2021-04-12
CN202110707739.6 2021-06-24
CN202110707739 2021-06-24
CN202111065912.3 2021-09-10
CN202111065912 2021-09-10
PCT/CN2022/086311 WO2022218296A1 (en) 2021-04-12 2022-04-12 Substituted fused bicyclic compounds as parp inhibitors and the use thereof

Publications (2)

Publication Number Publication Date
JP2024513538A JP2024513538A (ja) 2024-03-25
JP2024513538A5 true JP2024513538A5 (cg-RX-API-DMAC7.html) 2025-05-08

Family

ID=83640149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505487A Pending JP2024513538A (ja) 2021-04-12 2022-04-12 Parp阻害剤としての置換融合二環式化合物及びその使用

Country Status (8)

Country Link
US (1) US20240208969A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326713A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513538A (cg-RX-API-DMAC7.html)
KR (1) KR20240009929A (cg-RX-API-DMAC7.html)
CN (3) CN116783181B (cg-RX-API-DMAC7.html)
CA (1) CA3216489A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012039A (cg-RX-API-DMAC7.html)
WO (1) WO2022218296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050370A1 (en) * 2022-08-30 2024-03-07 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
WO2024099386A1 (zh) * 2022-11-10 2024-05-16 正大天晴药业集团股份有限公司 稠合双环化合物
TW202506680A (zh) * 2023-04-28 2025-02-16 美商思諾維新醫藥公司 作為parp1抑制劑之雜環化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6908398A (en) * 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
JP2001302515A (ja) * 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ(adp−リボース)ポリメラーゼ阻害剤
JP2002284699A (ja) * 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
DE602004014640D1 (de) * 2003-12-19 2008-08-07 Lilly Co Eli Tricyclische modulatoren von nuklearen steroidhormonrezeptoren
JP5100376B2 (ja) * 2004-06-30 2012-12-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキナゾリンジオン誘導体
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd 8−ヒドロキシ−2,4(1h,3h)−キナゾリンジオン誘導体
WO2009053373A1 (en) * 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009118384A1 (en) * 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
WO2011006803A1 (en) * 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd 2−アミノ置換8−オキソジヒドロプリン誘導体
US9090568B2 (en) * 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2,4-二酮作为parp抑制剂及其应用
TWI527800B (zh) * 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚(二磷酸腺苷酸-核醣)聚合酶(parp)之抑制劑之1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮及其應用
RU2014146993A (ru) * 2012-04-24 2016-06-10 Чугаи Сейяку Кабусики Кайся Производное хиназолиндиона
EP2913330A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2018036470A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 作为pde4抑制剂的并环类化合物
WO2018036469A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 Pde4抑制剂
WO2018112842A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
TW202039483A (zh) * 2018-11-22 2020-11-01 英屬開曼群島商百濟神州有限公司 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Similar Documents

Publication Publication Date Title
JP2024531477A5 (cg-RX-API-DMAC7.html)
EP3288558B1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
JP2025508122A5 (cg-RX-API-DMAC7.html)
AU2021202875B2 (en) Antiproliferative compounds, and their pharmaceutical compositions and uses
JP7539892B2 (ja) 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物
JP2025134754A (ja) Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類
BR112020008839A2 (pt) moduladores da via de estresse integrada
JP2020504139A5 (cg-RX-API-DMAC7.html)
TW201819386A (zh) Shp2磷酸酶抑制劑及其使用方法
RU2008146759A (ru) Производные дигидропиразолопиримидинона
JP2017513893A5 (cg-RX-API-DMAC7.html)
JP7611154B2 (ja) ピリド-ピリミジニル化合物及び使用の方法
JP2015523390A5 (cg-RX-API-DMAC7.html)
JP2010535201A (ja) 抗癌治療としての抗有糸分裂薬およびオーロラキナーゼ阻害薬
ES2895626T3 (es) Derivados de imidazol condensados como inhibidores de TGF-beta
EA031573B1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
JP2010512338A5 (cg-RX-API-DMAC7.html)
CN107864625A (zh) 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
CA2942636A1 (en) Macrocylic pyrimidine derivatives
KR20130069603A (ko) 종양 및 섬유증 질환 치료에서의 신규 병용 치료
JP2016509056A5 (cg-RX-API-DMAC7.html)
CN110475567A (zh) 抗癌组合疗法
JP2018501209A5 (cg-RX-API-DMAC7.html)
WO2018206547A1 (en) Combination of bub1 and atr inhibitors
CN114302878A (zh) 酪氨酸激酶非受体1(tnk1)抑制剂及其用途